Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Takeda Discontinues Development Of Cholesterol Compound

This article was originally published in PharmAsia News

Executive Summary

Takeda halted development of an investigational drug, TAK-475 (lapaquistat), for the treatment of high cholesterol, based on efficacy and safety data, the company announced March 28.

You may also be interested in...

Japanese Takeda Buys Abbott’s Stake In TAP Joint U.S. Venture

Japanese drug maker Takeda will establish Takeda America Holdings after finalizing a deal March 19 to obtain a 100 percent stake in TAP Pharmaceutical Products, its 50/50 joint venture with Abbott

Takeda Files DPP-4 Inhibitor NDA, Poised To Best Bristol/AstraZeneca, Novartis In Race For Second To Market

Takeda submitted an NDA for its dipeptidyl peptidase-4 inhibitor alogliptin (SYR-322) for type 2 diabetes Dec. 27, potentially positioning the Japanese pharma to be second to market with a drug in the class

Takeda Cholesterol Drug Filing Set Back Due To Liver Enzyme Data

A cholesterol drug Takeda had planned to file in the first quarter of 2008 has been delayed after elevated transaminase levels were seen in some patients taking a higher dose of the product in clinical trials, the Japanese firm announced Oct. 29. FDA has requested additional clinical trial data on TAK-475 (lapaquistat), a squalene synthase inhibitor

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts